With the upcoming legalization of recreational cannabis and the continuing establishment of medical cannabis, pharmacies in Germany face a range of challenges and opportunities. Especially with regard to compounded cannabis medicines, which play an important role in the treatment of chronic pain, spasticity and other serious conditions, the market will continue to develop. However, the rising number of prescriptions and the associated economics raise questions that not only concern pharmacists but could also affect patient care.

Economic Impact of Retaxation on Cannabis Compounded Prescriptions

Retaxation (the reduction of pharmacy claims by health insurers) has also caused considerable uncertainty in the field of cannabis compounded prescriptions. Pharmacies that offer cannabis products as compounded medicines are affected by this problem. One report described cases in which prescriptions that would have cost more than 100 euros were subsequently cut to 34 euros. For pharmacists this means financial losses, as the actual production costs are in many cases far above that amount. For smaller pharmacies without dedicated cannabis departments in particular, this can become an existential problem.

Cannabis preparations, especially those that are individually tailored (such as certain cannabis flowers or customized extracts), are expensive to produce. If health insurers do not reimburse these products adequately or set prices too low, pharmacies risk the business becoming unprofitable. As a result, less specialized pharmacies could withdraw from the cannabis market or reduce the number of compounded medicines they offer, which would impair patient care.

Specialization as a Success Factor for Pharmacies

For pharmacies that specialize in cannabis, the current market situation is not an insurmountable hurdle. On the contrary, pharmacies with a high volume of cannabis prescriptions and corresponding experience in working with health insurers and in pricing are better able to respond to the challenges. The complexity and individuality of cannabis compounded prescriptions require specific knowledge and expertise, skills that not every pharmacy possesses.

Specialized pharmacies often also have the advantage of access to a larger customer base, since their experience with cannabis products and their therapeutic use in patient care has earned them a good reputation. Thanks to their expertise and their connections with health insurers, these pharmacies can react more quickly to changes in the market and adapt to new regulatory frameworks.

Nevertheless, the question remains how prices for cannabis compounded prescriptions will develop and whether health insurers are willing to pay appropriate fees for producing individual cannabis preparations. If economic conditions remain unfavorable or deteriorate, even specialized pharmacies could come under pressure.

The Market Will Consolidate Further: Smaller Players Are at Risk

Developments in cannabis compounded prescriptions could lead to a consolidation of the market in the coming years. Pharmacies that run cannabis products only as a “side” business and have not built a specialized department for it will in all likelihood not be able to cope with the challenges of retaxation and uncertain pricing. These pharmacies could find themselves forced to discontinue their cannabis business or at least scale it back considerably.

On the other hand, pharmacies that have established cannabis as a core part of their business could benefit from growing demand for medical cannabis preparations. Through their specialization and experience, these pharmacies have a competitive advantage and could handle the existing market conditions better. Nevertheless, they too must closely monitor constant changes in pricing and their cooperation with health insurers in order to maintain profitability.

Outlook: What Can Be Expected?

The market for cannabis compounded prescriptions will continue to develop in the coming years, particularly against the backdrop of the legalization of recreational cannabis and growing medical use. For pharmacies, what will matter is how well they are able to respond to market conditions, adapt to the needs of their patients and create a sustainable economic basis for producing and dispensing cannabis products.

Specialization, experience and volume effects will remain key issues. Pharmacies that skillfully combine these factors while mastering the challenges of pricing and billing have the best chances of long-term success in the cannabis market.

For patients, it is to be hoped that despite these challenges the availability of cannabis preparations will be maintained and the quality of care will not suffer under economic pressure. One thing is clear, however: it will become increasingly difficult to run cannabis as merely a “side” business, and those who do so could soon have to withdraw from this market.